Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids
Open Access
- 27 October 2010
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 2 (4), 339-350
- https://doi.org/10.3390/pharmaceutics2040339
Abstract
Several biologically relevant phospholipids were assessed as potential carriers/additives for rapidly dissolving solid formulations of piroxicam (Biopharmaceutics Classification System Class II drug). On the basis of in vitro dissolution studies, dimyristoylphosphatidylglycerol (DMPG) was ranked as the first potent dissolution rate enhancer for the model drug. Subsequently, the solid dispersions of varying piroxicam/DMPG ratios were prepared and further investigated. Within the concentration range studied (6.4-16.7 wt %), the dissolution rate of piroxicam from the solid dispersions appeared to increase as a function of the carrier weight fraction, whereas the cumulative drug concentration was not significantly affected by piroxicam/DMPG ratio, presumably due to a unique phase behavior of the aqueous dispersions of this carrier phospholipid. Solid state analysis of DMPG-based formulations reveled that they are two-component systems, with a less thermodynamically stable form of piroxicam (Form II) being dispersed within the carrier. Finally, oral bioavailability of piroxicam from the DMPG-based formulations in rats was found to be superior to that of the control, as indicated by the bioavailability parameters, cmax and especially Tmax (53 µg/mL within 2 h vs. 39 µg/mL within 5.5 h, respectively). Hence, DMPG was regarded as the most promising carrier phospholipid for enhancing oral bioavailability of piroxicam and potentially other Class II drugs.Keywords
This publication has 30 references indexed in Scilit:
- Bimodal Release of Olanzapine from Lipid MicrospheresJournal of Pharmaceutical Sciences, 2010
- Salt formation to improve drug solubilityAdvanced Drug Delivery Reviews, 2007
- Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicamInternational Journal of Pharmaceutics, 2005
- Improving drug solubility for oral delivery using solid dispersionsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2000
- Properties of solid dispersions of piroxicam in polyvinylpyrrolidone K-30International Journal of Pharmaceutics, 1996
- Piroxicam-??-CyclodextrinDrugs, 1994
- Development of carbamazepine:phospholipid solid dispersion formulationsJournal of Controlled Release, 1993
- Improved Dissolution of Indomethacin in Coprecipitates with Phospholipids-IIDrug Development and Industrial Pharmacy, 1993
- Characteristics of Drug-Phospholipid Coprecipitates I: Physical Properties and Dissolution Behavior of Griseofulvin-Dimyristoylphosphatidylcholine SystemsJournal of Pharmaceutical Sciences, 1984
- Structure of the anti-inflammatory drug 4-hydroxy-2-methyl-N-2-pyridyl-2H-1λ6,2-benzothiazine-3-carboxamide 1,1-dioxide (piroxicam)Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 1982